This section of the FEDERAL REGISTER

contains documents other than rules or

proposed rules that are applicable to the

public. Notices of hearings and investigations,

committee meetings, agency decisions and

rulings, delegations of authority, filing of

petitions and applications and agency

statements of organization and functions are

examples of documents appearing in this

section.

Notices Federal Register

10332 

Vol. 87, No. 37 

Thursday, February 24, 2022 

COMMISSION ON CIVIL RIGHTS 

Notice of Public Meeting of the North 

Carolina Advisory Committee to the 

U.S. Commission on Civil Rights 

AGENCY: U.S. Commission on Civil 

Rights. 

ACTION: Announcement of virtual 

business meeting. 

SUMMARY: Notice is hereby given, 

pursuant to the provisions of the rules 

and regulations of the U.S. Commission 

on Civil Rights (Commission) and the 

Federal Advisory Committee Act, that 

the North Carolina Advisory Committee 

(Committee) to the U.S. Commission on 

Civil Rights will hold a virtual debrief 

via Webex at 12:00 p.m. ET on Friday, 

March 18, 2022, to discuss the March 

15, 2022, web briefing on Legal 

Financial Obligations in the state. 

DATES: The meeting will take place on 

Friday, March 18, 2022, at 12:00 p.m. 

ET. 

ADDRESSES: 

Online Registration (Audio/Visual): 

https://tinyurl.com/bdzh5sxs. 

Telephone (Audio Only): Dial (800) 

360–9505 USA Toll Free; Access code: 

2760 596 8002. 

FOR FURTHER INFORMATION CONTACT: 

Victoria Moreno, DFO, at vmoreno@

usccr.gov or (434) 515–0204. 

SUPPLEMENTARY INFORMATION: 

Committee meetings are available to the 

public through the conference link 

above. Any interested member of the 

public may listen to the meeting. An 

open comment period will be provided 

to allow members of the public to make 

a statement as time allows. If joining via 

phone, callers can expect to incur 

regular charges for calls they initiate 

over wireless lines, according to their 

wireless plan. The Commission will not 

refund any incurred charges. 

Individuals who are deaf, deafblind, and 

hard of hearing may also follow the 

proceedings by first calling the Federal 

Relay Service at (800) 877–8339 and 

providing the Service with the 

conference details found through 

registering at the web link above. To 

request additional accommodations, 

please email vmoreno@usccr.gov at least 

ten (10) days prior to the meeting. 

Members of the public are also 

entitled to submit written comments; 

the comments must be received in the 

regional office within 30 days following 

the meeting. Written comments may be 

emailed to Liliana Schiller at lschiller@

usccr.gov. Persons who desire 

additional information may contact the 

Regional Programs Coordination Unit at 

(312) 353–8311. 

Records generated from this meeting 

may be inspected and reproduced at the 

Regional Programs Coordination Unit, 

as they become available, both before 

and after the meeting. Records of the 

meeting will be available via 

www.facadatabase.gov under the 

Commission on Civil Rights, North 

Carolina Advisory Committee link. 

Persons interested in the work of this 

Committee are directed to the 

Commission’s website, http://

www.usccr.gov, or may contact the 

Regional Programs Coordination Unit at 

the above phone number. 

Agenda 

I. Welcome & Roll Call 

II. Panel Debrief 

III. Public Comment 

IV. Next Steps 

V. Adjournment 

Dated: Friday, February 17, 2022. 

David Mussatt, 

Supervisory Chief, Regional Programs Unit. 

[FR Doc. 2022–03860 Filed 2–23–22; 8:45 am] 

BILLING CODE 6335–01–P 

DEPARTMENT OF COMMERCE 

Foreign-Trade Zones Board 

[B–04–2022] 

Foreign-Trade Zone (FTZ) 177— 

Evansville, Indiana; Notification of 

Proposed Production Activity; 

AstraZeneca Pharmaceuticals, LP; 

(Pharmaceutical Products); Mount 

Vernon, Indiana 

AstraZeneca Pharmaceuticals, LP 

submitted a notification of proposed 

production activity to the FTZ Board 

(the Board) for its facility in Mount 

Vernon, Indiana within Subzone 177A. 

The notification conforming to the 

requirements of the Board’s regulations 

(15 CFR 400.22) was received on 

February 14, 2022. 

Pursuant to 15 CFR 400.14(b), FTZ 

production activity would be limited to 

the specific foreign-status materials and 

specific finished products described in 

the submitted notification (summarized 

below) and subsequently authorized by 

the Board. The benefits that may stem 

from conducting production activity 

under FTZ procedures are explained in 

the background section of the Board’s 

website—accessible via www.trade.gov/ 

ftz. The proposed finished products and 

materials would be added to the 

production authority that the Board 

previously approved for the operation, 

as reflected on the Board’s website. 

The proposed finished products 

include: ARIMIDEX (anastrozole) 

tablets; BRILINTA (ticagrelor) tablets; 

CRESTOR (rosuvastatin calcium) 

tablets; LYNPARZA (olaparib) tablets; 

SEROQUEL IR (quetiapine fumarate) 

tablets; and, SEROQUEL XR (quetiapine 

fumarate) tablets (duty-free). 

The proposed foreign-status materials 

include: Anastrozole active 

pharmaceutical ingredient (API); 

microcrystalline cellulose; olaparib API; 

quetiapine fumarate API; rosuvastatin 

calcium API; and, ticagrelor API (duty 

rate ranges from 5.2% to 6.5%). The 

request indicates that olaparib API and 

ticagrelor API are subject to duties 

under Section 301 of the Trade Act of 

1974 (Section 301), depending on the 

country of origin. The applicable 

Section 301 decisions require subject 

merchandise to be admitted to FTZs in 

privileged foreign status (19 CFR 

146.41). 

Public comment is invited from 

interested parties. Submissions shall be 

addressed to the Board’s Executive 

Secretary and sent to: ftz@trade.gov. The 

closing period for their receipt is April 

5, 2022. 

A copy of the notification will be 

available for public inspection in the 

‘‘Online FTZ Information System’’ 

section of the Board’s website. 

For further information, contact 

Christopher Wedderburn at 

Chris.Wedderburn@trade.gov. 


jspears on DSK121TN23PROD with NOTICES1